Doctor Leucht studied medicine in Munich, Germany, Cape Town, South Africa, Alicante Spain, and Atlanta, USA. He is head of the Section of Evidence-Based Medicine in Psychiatry and Psychotherapy at the Department of Psychiatry and Psychotherapy of the Technical University of Munich, Germany, where he has practiced since 1994 and now runs the “Section Evidence-Based Medicine in Psychiatry and Psychotherapy”. He worked as a research associate at the Zucker Hillside Hospital, in New York in 2002/2003. He spent a year as honorary fellow at the University Department of Psychiatry in Oxford, he held a position of honorary professor of Evidence-based Psychopharmacology at the University of Aarhus, Denmark until 2019 and he is currently visiting professor at the Institute of Psychiatry, King’s College London and at Shanghai Jiao Tong University School of Medicine, Shanghai, China. He is part of the editorial teams of several psychiatric journals, including the Cochrane Schizophrenia Group, Lancet Psychiatry, Schizophrenia Research, Schizophrenia Bulletin, Acta Psychiatrica Scandinavica, International Clinical Psychopharmacology, European Neuropsychopharmacology and European Psychiatry. Since inception of the ranking in 2014 Thompson Reuters has named Dr. Leucht on their list of the World’s Most Influential Minds, as ranking in the top 1% citations for the field of psychiatry, and as a Highly Cited Researcher. In 2020 Expertscape (http://expertscape.com/ex/schizophrenia) ranked him among the top ten schizophrenia researchers. He led the schizophrenia guideline group of the College of International Neuropsychopharmacology (CINP) and. He was awarded the David Sackett Award of the German Network of Evidence-Based Medicine in 2010, The American Psychiatric Association Young Minds in Psychiatry Award in 2004, and the Robert Kerwin Award of the Royal College of Psychiatry in 2012. The overarching theme of Dr. Leucht's research is and evidence-based medicine in psychiatry with a focus on meta-analyses, clinical trials and the improvement of methodology of studies in this area. He also has a research interest in pharmacogenetics, compliance enhancement strategies and medical decision making.